Nov 3, 2009 - Updated corporate presentation at Bio Europe (Wien, Austria)   


Sept 20, 2009 - Update of five clinical trials of NGR-hTNF presented at ECCO-ESMO 2009   15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology, Internationale Congress Centrum Berlin (ICC Berlin), Berlin, Germany.


Sept 17, 2009 - Presentation to the financial community delivered at Stock Market Opportunities Conference, Milan, 17 September 2009   


Sept 14, 2009 - Company presentation at the 9th Annual Biotech in Europe Investor Forum, Zurich, 14-15 September 2009   


Aug 2, 2009 - Gordon Research Conference on Angiogenesis - Newport, 02-07 August 2009   
MolMed presented a poster on the mechanism of action of NGR-hTNF


Jul 2, 2009 - Results of Phase I of NGR-hTNF in combination with doxorubicin published by the British Journal of Cancer   
Results of Phase I trial of NGR-hTNF in combination with doxorubicin, conducted in heavily pre-treated patients affected by advanced solid tumours, published by the British Journal of Cancer


Jun 23, 2009 - China BioPartnering Forum (Shanghai), 23-24 June 2009   MolMed gave a company presentation


May 29, 2009 - ASCO 2009 (Orlando), 29 May-2 June 2009   45th American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando.


May 20, 2009 - Company presentation delivered at BIO 2009   


Apr 18, 2009 - AACR (American Association for Cancer Research) 2009 (Denver, 18 - 22 April 2009)   MolMed gave an oral presentation on the mechanism of action of NGR-hTNF: "NGR-hTNF selectively binds to tumor blood vessels via CD13, inducing the activation of caspases and promoting apoptotic endothelial cell death in vivo"


Apr 1, 2009 - International Conference on Targeted Therapies in Lung Cancer (Saint Paul de Vence, 1-5 April 2009)   MolMed gave a presentation on the clinical trials of NGR-hTNF


Mar 17, 2009 - Presentation to the financial community, Milan, 17 March 2009   


Mar 16, 2009 - BIO Europe Spring, Milan, 16-18 March 2009   MolMed gave a company presentation


Mar 9, 2009 - Biosquare (Lyon, 9-11 March 2009)   MolMed gave a company presentation


Feb 9, 2009 - BIO CEO & Investor Conference (New York, 9-10 February 2009)   MolMed gave a company presentation


Feb 8, 2009 - BioPartnerig North America (Vancouver, 8-10 February 2009)   MolMed gave a company presentation


Feb 5, 2009 - International Symposium on Anti-Angiogenic Agents (San Diego, 5-7 February 2009)   MolMed gave an oral presentation on the mechanism of action of NGR-hTNF



Feb 3, 2009 - European Life Science CEO Forum (Zurich, 3-4 February 2009)   MolMed gave a company presentation



Jan 15, 2009 - ASCO GI Symposium (San Francisco, 15-17 January 2009)   MolMed exhibited 2 posters on its Phase II clinical trials of NGR-hTNF in colorectal cancer and in liver cancer


Jan 12, 2009 - JP Morgan Conference (San Francisco, 12-16 January 2009)   MolMed attended the conference

ARCHIVE

| 2010 | 2009 | 2008 | 2007 |